Semaglutide vs MK-677 (Ibutamoren)

A GLP-1 receptor agonist originally approved for type 2 diabetes and now widely used for chronic weight management, producing 15%+ reductions in body weight over 12 months in clinical trials.

An orally active ghrelin receptor agonist that mimics growth hormone secretagogues without injections. Technically a small molecule, but included because it dominates GH-secretagogue conversations alongside CJC-1295/ipamorelin.

Semaglutide mimics the incretin hormone GLP-1, slowing gastric emptying, reducing appetite via hypothalamic signalling, and enhancing glucose-dependent insulin secretion. The result is sustained calorie reduction without conscious restriction.

MK-677 binds the ghrelin receptor (GHSR-1a), triggering GH and IGF-1 elevation. Unlike peptide secretagogues, it's orally bioavailable.

0.25 mg weekly, titrated up to 2.4 mg weekly for weight loss

10–25 mg oral, once daily (usually bedtime)

~7 days

~24 hours

Subcutaneous once weekly, Oral (lower bioavailability)

Oral

approved

research-only

Not yet listed

Not yet listed